Ying Pang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11544257/publications.pdf

Version: 2024-02-01

28	640	623734	642732
papers	citations	14 h-index	23 g-index

28	28	28	1073
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	6.3	21
2	Targeting CDK9 for the Treatment of Glioblastoma. Cancers, 2021, 13, 3039.	3.7	12
3	Report of Canonical BCR-ABL1 Fusion in Glioblastoma. JCO Precision Oncology, 2021, 5, 1348-1353.	3.0	3
4	Tumor mutational burden and immunotherapy in gliomas. Trends in Cancer, 2021, 7, 1054-1058.	7.4	15
5	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers, 2021, 13, 6092.	3.7	14
6	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. International Journal of Cancer, 2020, 146, 2326-2335.	5.1	14
7	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. Neurology: Genetics, 2020, 6, e414.	1.9	5
8	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	4.5	23
9	Therapeutic Targeting ofSDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	7.0	29
10	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neuro-Oncology Advances, 2020, 2, vdaa065.	0.7	16
11	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2020, 12, 280.	3.7	23
12	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. Journal of Bone and Mineral Research, 2020, 36, 315-321.	2.8	9
13	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology, 2020, 10, 601452.	2.8	1
14	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
15	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. International Journal of Molecular Sciences, 2019, 20, 2819.	4.1	8
16	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers, 2019, 11, 654.	3.7	21
17	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	3.7	33
18	Nonmosaic somatic HIF2A mutations associated with late onset polycythemiaâ€paraganglioma syndrome: Newly recognized subclass of polycythemiaâ€paraganglioma syndrome. Cancer, 2019, 125, 1258-1266.	4.1	11

#	Article	IF	Citations
19	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	3.6	27
20	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. , 2018, 188, 168-175.		40
21	Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432.	7.0	57
22	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. Cancer Research, 2018, 78, 1266-1274.	0.9	16
23	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286.	2.6	15
24	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	2.3	7
25	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget, 2017, 8, 22313-22324.	1.8	29
26	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget, 2017, 8, 56110-56125.	1.8	64
27	Ischemia preconditioning protects astrocytes from ischemic injury through 14â€3â€3Î³. Journal of Neuroscience Research, 2015, 93, 1507-1518.	2.9	11
28	Calcium Signaling Involvement in Cadmium-Induced Astrocyte Cytotoxicity and Cell Death Through Activation of MAPK and PI3K/Akt Signaling Pathways. Neurochemical Research, 2015, 40, 1929-1944.	3.3	56